Samson et al (2003) reviewed the evidence regarding NB-UVB for the treatment for vitiligo, pruritus, and inflammatory dermatoses. This was a retrospective review of the treatment outcomes of 117 consecutive patients with vitiligo, pruritus, and other inflammatory dermatoses, excluding those with psoriasis and cutaneous T-cell lymphoma (CTCL), who were treated with NB-UVB between 1998 and 2001 at the authors’ institution.
Approximately 80% of all patients showed improvement in their condition. Narrow-band UVB phototherapy was well-tolerated, with no serious adverse effects. In patients with vitiligo, 6.4% had an abnormal thyroid-stimulating hormone level and 6.5% had anemia.
The authors concluded that NB-UVB may be considered as a viable therapeutic option in the treatment of vitiligo, pruritus, and other inflammatory dermatoses. Moreover, they stated that long-term adverse effects and cost-benefit analysis of NB-UVB therapy compared to other treatment modalities remain to be determined.
References
- https://www.aetna.com/cpb/medical/data/200_299/0205.html
- Samson Yashar S, Gielczyk R, Scherschun L, Lim HW. Narrow-band ultraviolet B treatment for vitiligo, pruritus, and inflammatory dermatoses. Photodermatol Photoimmunol Photomed. 2003;19(4):164-168.
